Wegovy and Zepbound are still hard to get. Knockoff versions from Noom, Ro, and others are filling in the gaps.

The weight-loss market is heating up as a number of companies are looking for a way to upend the dominance of market leaders Novo Nordisk (NVO) and Eli Lilly (LLY) by introducing GLP-1 pills.

The popularity of GLP-1 weight loss drugs has soared, which had created a shortage among many of the drugs, including Eli ...

PBMs are putting weight loss drugs, including Wegovy and Zepbound, on their national formularies, but coverage by plans is ...

That’s according to a new Employer Health Benefits Survey from KFF (formerly the Kaiser Family Foundation). But while a ...

The FDA updated its database of drugs in shortage to remove tirzepatide, which had sat on that list – along with related ...

If you or someone you know has diabetes, you’ve likely heard of metformin, a drug that’s primarily prescribed to support ...

Losing weight may seem simple: engage in regular physical activity and exercise and eat a balanced diet that contains ...

Popular weight-loss medications including Ozempic and Wegovy contain a drug that seems to decrease cravings for food and ...

Looking at the data from clinical trials of new GLP-1 agonists ... After 36 weeks on the drug, 670 patients had mean weight loss of 20.9%. They were then randomized to stay on the drug or switch ...

While Ozempic – the branded name for a drug called semaglutide - was designed to treat type two diabetes, it’s also been ...

Jean Readdy, a retired teacher living in Sinking Spring, Pennsylvania, is among the one in eight Americans who have tried a GLP-1 drug for weight loss or ... one of a growing number of people ...